NovaQuest Capital Management provides a range of customized, structured finance investments to meet the needs of BioPhama companies.
Business Model:
Revenue: $6.5M
Employees: 11-50
Address: 4208 Six Forks Road
City: Raleigh
State: NC
Zip: 27609
Country: US
NovaQuest Capital Management, LLC (NovaQuest) manages product and company investments in the global healthcare industry. Its primary focus is structured finance investments in late-stage clinical and commercialized biopharmaceutical products. NovaQuest invests side-by-side with global companies in their most strategic product programs, ensuring alignment with the biopharmaceutical companies. These customized, product transactions are an alternative to standard biopharmaceutical industry deal-making and help companies maximize the value of their product portfolios. In addition, NovaQuest invests in select private equity and other company securities, with a consistent focus on late-stage clinical and commercialized products. The NovaQuest team has worked together for over 12 years, investing over $1 billion into the global healthcare industry. The team began pursuing its strategy in 2000 as an investment group within Quintiles Transnational Holdings Inc. (Quintiles). Today, NovaQuest Capital Management is an independent firm managing global investment capital. It is backed by investors whose relationships with NovaQuest date back to the group’s inception. NovaQuest is meeting the evolving needs of global healthcare companies and its investors with a consistent strategy, developed over multiple years and transactions, that draws on a customized mix of investment and return elements and securities.
Contact Phone:
+19194598620
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
7/2022 | Hansa Biopharma | Grant | 0 |
6/2021 | Dermavant Sciences | Private Equity Round | 0 |
11/2022 | Phathom Pharmaceuticals | Post-IPO Debt | 40M |
5/2018 | Clinical Ink | Private Equity Round | 5.3M |
9/2013 | PreCision Dermatology | Debt Financing | 67M |
12/2019 | InformedDNA | Venture Round | - |
11/2018 | Roivant Sciences | Private Equity Round | 0 |
7/2018 | Mesoblast | Post-IPO Equity | 50M |
10/2017 | Myovant Sciences | Post-IPO Equity | 100M |
10/2020 | Mileutis | Corporate Round | 20M |
6/2011 | Revance Therapeutics | Series D | 45M |
5/2022 | TARGAN | Series C | 0 |
5/2021 | Argenta | Private Equity Round | 0 |
5/2021 | Aceragen | Private Equity Round | 0 |
4/2021 | Cerevel Therapeutics | Post-IPO Equity | 0 |
5/2020 | Arvelle Therapeutics | Series A | 0 |
5/2011 | BioCritica | Private Equity Round | 25M |
6/2019 | Nevakar | Private Equity Round | 0 |
7/2022 | Hansa Biopharma | Grant | 0 |
5/2022 | TARGAN | Series C | 0 |
6/2021 | Dermavant Sciences | Private Equity Round | 0 |
5/2021 | Argenta | Private Equity Round | 0 |
5/2021 | Aceragen | Private Equity Round | 0 |
4/2021 | Cerevel Therapeutics | Post-IPO Equity | 0 |
10/2020 | Mileutis | Venture Round | 0 |
5/2020 | Arvelle Therapeutics | Series A | 0 |
12/2019 | InformedDNA | Venture Round | - |
6/2019 | Nevakar | Private Equity Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|